138 related articles for article (PubMed ID: 32184669)
1. LncRNA NCK1-AS1 Promotes Cancer Cell Proliferation and Increase Cell Stemness in Urinary Bladder Cancer Patients by Downregulating miR-143.
Qiao Z; Dai H; Zhang Y; Li Q; Zhao M; Yue T
Cancer Manag Res; 2020; 12():1661-1668. PubMed ID: 32184669
[TBL] [Abstract][Full Text] [Related]
2. LncRNA NCK1-AS1 promotes non-small cell lung cancer progression via regulating miR-512-5p/p21 axis.
Luo X; Zhou J; Quan L; Liang Y; Huang P; Chen F; Liu S
Pathol Res Pract; 2020 Nov; 216(11):153157. PubMed ID: 32858372
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA NCK1-AS1 promotes the proliferation, migration and invasion of non-small cell lung cancer cells by acting as a ceRNA of miR-137.
Li J; Wu X; Cao W; Zhao J
Am J Transl Res; 2020; 12(10):6908-6920. PubMed ID: 33194081
[TBL] [Abstract][Full Text] [Related]
4. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
Zhang WY; Liu YJ; He Y; Chen P
J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
[TBL] [Abstract][Full Text] [Related]
5. Knockdown Of lncRNA NCK-AS1 Regulates Cisplatin Resistance Through Modulating miR-137 In Osteosarcoma Cells.
Cheng Y; Shen X; Zheng M; Zou G; Shen Y
Onco Targets Ther; 2019; 12():11057-11068. PubMed ID: 31908475
[TBL] [Abstract][Full Text] [Related]
6. NCK1-AS1 promotes the progression of melanoma by accelerating cell proliferation and migration via targeting miR-526b-5p/ADAM15 axis.
Lin Q; Jia Y; Zhang D; Jin H
Cancer Cell Int; 2021 Jul; 21(1):367. PubMed ID: 34247598
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of NCK1-AS1 inhibits the development of atherosclerosis by targeting miR-1197/COX10 axis.
Zhang B; Wang J; Du L; Shao L; Zou Y; Liu H; Liu J
J Biol Eng; 2022 Jan; 16(1):2. PubMed ID: 34986861
[TBL] [Abstract][Full Text] [Related]
8. LncRNA NCK1-AS1 promotes proliferation and induces cell cycle progression by crosstalk NCK1-AS1/miR-6857/CDK1 pathway.
Li H; Jia Y; Cheng J; Liu G; Song F
Cell Death Dis; 2018 Feb; 9(2):198. PubMed ID: 29416014
[TBL] [Abstract][Full Text] [Related]
9. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
10. Upregulation of lncRNA NCK1-AS1 predicts poor prognosis and contributes to non-small cell lung cancer proliferation by regulating CDK1.
Zha LF; Zhang LD; Pan HM; Ma HD
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1351-1357. PubMed ID: 33629305
[TBL] [Abstract][Full Text] [Related]
11. Long Non-Coding RNA NCK1-AS1 Serves an Oncogenic Role in Gastric Cancer by Regulating miR-137/NUP43 Axis.
Li W; Duan J; Shi W; Lei L; Lv P
Onco Targets Ther; 2020; 13():9929-9939. PubMed ID: 33116577
[TBL] [Abstract][Full Text] [Related]
12. The role and clinical significance of long noncoding RNA zinc finger E-box-binding homeobox two antisense RNA 1 in promoting osteosarcoma cancer cell proliferation, inhibiting apoptosis and increasing migration by regulating miR-145.
Zhou Y; Feng D; Gu X; Gao A; Liu Y
Anticancer Drugs; 2021 Feb; 32(2):168-177. PubMed ID: 32826416
[TBL] [Abstract][Full Text] [Related]
13. LncRNA NCK1-AS1 in plasma distinguishes oral ulcer from early-stage oral squamous cell carcinoma.
Le F; Ou Y; Luo P; Zhong X
J Biol Res (Thessalon); 2020 Dec; 27():16. PubMed ID: 33194849
[TBL] [Abstract][Full Text] [Related]
14. Silencing of long non-coding RNA NCK1-AS1 inhibits cell proliferation and migration via inhibition of microRNA-134 in cervical cancer.
Huang L; Gan X; He L; Wang L; Yu J
Exp Ther Med; 2019 Sep; 18(3):2314-2322. PubMed ID: 31410182
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of lncRNA NCK1-AS1 Inhibits Cancer Cell Migration and Invasion in Nasopharyngeal Carcinoma by Upregulating miR-135a.
Hu H; Li H; Feng X
Cancer Manag Res; 2019; 11():10531-10537. PubMed ID: 31908525
[TBL] [Abstract][Full Text] [Related]
16. NCK1-AS1 enhances glioma cell proliferation, radioresistance and chemoresistance via miR-22-3p/IGF1R ceRNA pathway.
Wang B; Wang K; Jin T; Xu Q; He Y; Cui B; Wang Y
Biomed Pharmacother; 2020 Sep; 129():110395. PubMed ID: 32887025
[TBL] [Abstract][Full Text] [Related]
17. Long Noncoding RNA KCNMB2-AS1 Promotes SMAD5 by Targeting miR-3194-3p to Induce Bladder Cancer Progression.
Chen YS; Xu YP; Liu WH; Li DC; Wang H; Li CF
Front Oncol; 2021; 11():649778. PubMed ID: 34026626
[TBL] [Abstract][Full Text] [Related]
18. AS1 expression in prostate cancer and its effects on proliferation and invasion of prostate cancer cells.
Li Y; Zhuang X; Zhuang L; Liu H
Cancer Biomark; 2021; 32(3):271-279. PubMed ID: 34151833
[TBL] [Abstract][Full Text] [Related]
19. NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.
Chang H; Li B; Zhang X; Meng X
Biochem Biophys Res Commun; 2020 Feb; 522(2):292-299. PubMed ID: 31761329
[TBL] [Abstract][Full Text] [Related]
20. LncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b.
Wu X; Yan T; Wang Z; Wu X; Cao G; Zhang C
Biomed Pharmacother; 2017 Dec; 96():299-304. PubMed ID: 28992472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
